These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 3565312)

  • 1. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    Abdi EA; Hanson J; McPherson TA
    Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
    Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
    Czarnetzki BM; Aragon V; Bröcker EB; Krieg V; Bünte H; Macher E
    Dtsch Med Wochenschr; 1986 May; 111(19):732-6. PubMed ID: 3698850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and treatment of regional lymphatic metastasis of cutaneous melanoma].
    Korovin SI; Tolstopiatov BA
    Klin Khir (1962); 1993; (5):34-6. PubMed ID: 7933861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
    Cochran AJ; Buyse ME; Lejeune FJ; Macher E; Revuz J; Rümke P
    Int J Cancer; 1981 Nov; 28(5):543-50. PubMed ID: 7309294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
    Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
    Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
    Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
    Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.